Effect of Anthocyanins Supplementation on Serum IGFBP-4 Fragments and Glycemic Control in Patients with Fasting

Related Experiment Video

Updated: Dec 5, 2025

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

565

Liping Yang1,2, Zhaomin Liu2, Wenhua Ling2

  • 1Center for Chronic Disease Control, Nanshan, Shenzhen, People's Republic of China.

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|October 16, 2020
PubMed
Abstract

Insights

Anthocyanin supplementation improved insulin-like growth factor binding protein-4 (IGFBP-4) fragments and fasting glucose in individuals with hyperglycemia. This study suggests anthocyanins may benefit cardiometabolic health.

Area of Science:

  • Endocrinology
  • Nutritional Science
  • Metabolic Health

Background:

  • Insulin-like growth factor binding protein-4 (IGFBP-4) fragments are linked to cardiometabolic diseases.
  • Anthocyanins, natural polyphenols, show potential in managing cardiometabolic conditions.

Purpose of the Study:

  • To investigate the impact of purified anthocyanins on serum IGFBP-4 fragments.
  • To assess the effects of anthocyanins on glycemic control in patients with fasting hyperglycemia.

Main Methods:

  • A 12-week randomized controlled trial involving 121 participants with elevated fasting glucose.
  • Participants received either 320 mg/day of anthocyanins or a placebo.
  • Measurements included serum IGFBP-4 fragments, glucose, insulin, and C-peptide via oral glucose tolerance test (OGTT).

Main Results:

  • Anthocyanins significantly increased serum IGFBP-4 fragments compared to placebo (net change 8.33 ng/mL, p=0.023).
  • Anthocyanin supplementation reduced fasting glucose (p=0.01) and postload C-peptide levels (2-hour: p=0.041; 3-hour AUC: p=0.026).
  • No significant differences were observed in other glycemic control or insulin resistance parameters.

Conclusions:

  • A 12-week anthocyanin supplementation improved serum IGFBP-4 fragments and glycemic control markers in patients with fasting hyperglycemia.
  • Findings suggest a potential role for anthocyanins in managing cardiometabolic health.
  • Further research is warranted to confirm these results and elucidate the underlying mechanisms.
Keywords:
C-peptideIGFBP-4 fragmentsanthocyanininsulin resistanceoral glucose tolerance test

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

70.7K
Using a Combination of Indirect Calorimetry, Infrared Thermography, and Blood Glucose Levels to Measure Brown Adipose Tissue Thermogenesis in Humans04:54

Using a Combination of Indirect Calorimetry, Infrared Thermography, and Blood Glucose Levels to Measure Brown Adipose Tissue Thermogenesis in Humans

Published on: June 2, 2023

1.8K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
421
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
433
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
660